report-image

Alectinib Market Analysis by Indication (Non-Small Cell Lung Cancer (NSCLC), Other Cancers), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Patient Type (Adult Patients, Pediatric Patients), by End User (Oncology Clinics, Hospitals, Cancer Research Institutes) and by Region: Global Forecast, 2024 - 2034

  • PUBLISHED ON
  • 2024-04-29
  • NO OF PAGES
  • 191
  • CATEGORY
  • Healthcare & Life Sciences

Market Overview

The Alectinib market is predicted to develop at a compound annual growth rate (CAGR) of XX% from 2024 to 2034, when it is projected to reach USD XX Million, based on an average growth pattern. The market is estimated to reach a value of USD XX Million in 2024.

 

SOURCE: We Market Research

The U.S. Food and Drug Administration (FDA) approved alexinatib in 2015 for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who had progressed on crizotinib or were intolerant to it. Alectinib was first developed by Chugai Pharmaceutical Co., Ltd. Promising clinical trial data that showed the medication's safety profile and efficacy in this patient population served as the foundation for approval. Alectinib functions by specifically blocking the ALK protein, which is frequently responsible for promoting the development of NSCLCs that are positive for ALK. As alectinib has demonstrated better efficacy and tolerability than previous ALK inhibitors such as crizotinib, it has gradually evolved into the standard of care for the treatment of ALK-positive non-small cell lung cancer.

The market is driven by the exceptional effectiveness and favorable safety profile of alectinib, a targeted therapy for non-small cell lung cancer (NSCLC) that is positive for ALK. Physician preference for alelectinib has grown due to its ability to selectively target ALK-positive cancers, which has resulted in better results and longer progression-free survival. Alectinib's potential uses are further expanded by ongoing clinical trials investigating its use in various therapy situations. The market's expansion is also fueled by regulatory approvals for more widespread indications and developments in precision medicine. Alectinib's market is still growing as a top cancer therapy choice because there are more and more ALK-positive NSCLC patients looking for safe and effective treatments. 

Market Scope

Report Attributes

Description

Market Size in 2024

USD XX Million

Market Forecast in 2034

USD XX Million

CAGR % 2024-2034

XX%

Base Year

2023

Historic Data

2016-2022

Forecast Period

2024-2034

Report USP

 

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

By Indication, by Distribution Channel, by Patient Type, by End User and By Region

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

 

Alectinib Industry: Dynamics & Restrains


 Market opportunity:


 

We Market Research: Alectinib Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.


Alectinib Segmentation

Market- By Indication Analysis

By Indication, the Alectinib Market is Categories into Non-Small Cell Lung Cancer (NSCLC), Other Cancers. The Non-Small Cell Lung Cancer (NSCLC) segment accounts for the largest share of around 94% in 2024.


Alexib, a targeted therapy for ALK-positive non-small cell lung cancer (NSCLC), is gaining popularity in the treatment of NSCLC due to its improved efficacy, reduced side effects, and higher capacity to cure brain metastases. Expanded indications and guidelines' support further aid in its adoption since it tackles problems such as resistance mutations in later cycles of medication.

The following segments are part of an in-depth analysis of the global Alectinib market:

Market Segments

 

By  Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

Patient Type

·         Adult Patients

·         Pediatric Patients

By  End User

·         Oncology Clinics

·         Hospitals

·         Cancer Research Institutes

 

Alectinib Industry: Regional Analysis

North America Market Forecast

North America dominate the Alectinib Market with the highest revenue generating market with share of more than 49%. North America dominates the Alectinib market because of its high healthcare spending, well-established treatment protocols, and broad use of targeted medicines like Alectinib, this area presently controls the majority of the global Alectinib market.


Europe Market Statistics

Europe is the second largest region in Alectinib market. The European alexib market is expanding due to a number of factors, including regulatory approvals, favorable reimbursement policies, and growing awareness of targeted medications. Alliances between the healthcare provider and industry, as well as mounting clinical evidence of alelectinib's effectiveness, are driving its adoption and facilitating patient access.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing regional segment of the Alectinib market during the forecast period. The Asia-Pacific market for alexib is expanding quickly due to a large and growing patient population with non-small cell lung cancer (NSCLC), increased access to cutting-edge treatments, and rising healthcare expenditures. Market dynamics are influenced by regional differences in healthcare infrastructure, whereas regulatory approvals and clinical studies are the primary drivers of awareness and acceptance.

Key Market Players:

Roche

1.      Global Alectinib Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Alectinib Market Scope and Market Estimation

1.2.1. Global Alectinib Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Alectinib Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Component of Global Alectinib Market

1.3.2. Technology of Global Alectinib Market

1.3.3. Patient Type of Global Alectinib Market

1.3.4. Region of Global Alectinib Market

2.      Executive Summary

2.1.    Global Alectinib Market Industry Trends under COVID-19 Outbreak

2.1.1. Global COVID-19 Status Overview

2.1.2. Influence of COVID-19 Outbreak on Global Alectinib Market Industry Development

2.2.    Market Dynamics

2.2.1. Drivers

2.2.2. Limitations

2.2.3. Opportunities

2.2.4. Impact Analysis of Drivers and Restraints

2.3.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.    Porter’s Five Forces Analysis

2.5.1. Bargaining Power of Suppliers

2.5.2. Bargaining Power of Buyers

2.5.3. Threat of Substitutes

2.5.4. Threat of New Entrants

2.5.5. Competitive Rivalry

2.6.    Value Chain / Ecosystem Analysis

2.7.    Russia-Ukraine War Impacts Analysis

2.8.    Economic Downturn Analysis

2.9.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Alectinib Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Alectinib Market Estimates & Forecast Trend Analysis, by INDICATION

4.1.    Global Alectinib Market Revenue (US$ Mn) Estimates and Forecasts, by INDICATION, 2019 to 2034

4.1.1. Non-Small Cell Lung Cancer (NSCLC

4.1.2. Other Cancers

5.      Global Alectinib Market Estimates & Forecast Trend Analysis, by Distribution Channel

5.1.    Global Alectinib Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2034

5.1.1. Hospital Pharmacies

5.1.2. Retail Pharmacies

5.1.3. Online Pharmacies

6.      Global Alectinib Market Estimates & Forecast Trend Analysis, by Patient Type

6.1.    Global Alectinib Market Revenue (US$ Mn) Estimates and Forecasts, by Patient Type, 2019 to 2034

6.1.1. Adult Patients

6.1.2. Pediatric Patients

7.      Global Alectinib Market Estimates & Forecast Trend Analysis, by END USER

7.1.    Global Alectinib Market Revenue (US$ Mn) Estimates and Forecasts, by Patient Type, 2019 to 2034

7.1.1. Oncology Clinics

7.1.2. Hospitals

7.1.3. Cancer Research Institutes

8.      Global Alectinib Market Estimates & Forecast Trend Analysis, by Region

8.1.    Global Alectinib Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034

8.1.1. North America

8.1.2. Europe

8.1.3. Asia Pacific

8.1.4. Middle East & Africa

8.1.5. South America

9.      North America Alectinib Market: Estimates & Forecast Trend Analysis

9.1.    North America Alectinib Market Assessments & Key Findings

9.1.1. North America Alectinib Market Introduction

9.1.2. North America Alectinib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By INDICATION

9.1.2.2.   By Distribution Channel

9.1.2.3.   By Patient Type

9.1.2.4.   By END USER

9.1.2.5.   By Country

9.1.2.5.1.     The U.S.

9.1.2.5.2.     Canada

9.1.2.5.3.     Mexico

10.  Europe Alectinib Market: Estimates & Forecast Trend Analysis

10.1.  Europe Alectinib Market Assessments & Key Findings

10.1.1.   Europe Alectinib Market Introduction

10.1.2.   Europe Alectinib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By INDICATION

10.1.2.2.    By Distribution Channel

10.1.2.3.    By Patient Type

10.1.2.4.    By END USER

10.1.2.5.    By Country

10.1.2.5.1. Germany

10.1.2.5.2. U.K.

10.1.2.5.3. France

10.1.2.5.4. Italy

10.1.2.5.5. Spain

10.1.2.5.6. Russia

10.1.2.5.7. Rest of Europe

11.  Asia Pacific Alectinib Market: Estimates & Forecast Trend Analysis

11.1.  Asia Pacific Market Assessments & Key Findings

11.1.1.   Asia Pacific Alectinib Market Introduction

11.1.2.   Asia Pacific Alectinib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By INDICATION

11.1.2.2.    By Distribution Channel

11.1.2.3.    By Patient Type

11.1.2.4.    By END USER

11.1.2.5.    By Country

11.1.2.5.1. China

11.1.2.5.2. Japan

11.1.2.5.3. India

11.1.2.5.4. Australia

11.1.2.5.5. South Korea

11.1.2.5.6. ASEAN

11.1.2.5.7. Rest of Asia Pacific

12.  Middle East & Africa Alectinib Market: Estimates & Forecast Trend Analysis

12.1.  Middle East & Africa Market Assessments & Key Findings

12.1.1.   Middle East & Africa Alectinib Market Introduction

12.1.2.   Middle East & Africa Alectinib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By INDICATION

12.1.2.2.    By Distribution Channel

12.1.2.3.    By Patient Type

12.1.2.4.    By END USER

12.1.2.5.    By Country

12.1.2.5.1. U.A.E.

12.1.2.5.2. Saudi Arabia

12.1.2.5.3. Egypt

12.1.2.5.4. South Africa

12.1.2.5.5. Rest of Middle East & Africa

13.  South America Alectinib Market: Estimates & Forecast Trend Analysis

13.1.  South America Market Assessments & Key Findings

13.1.1.   South America Alectinib Market Introduction

13.1.2.   South America Alectinib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

13.1.2.1.    By INDICATION

13.1.2.2.    By Distribution Channel

13.1.2.3.    By Patient Type

13.1.2.4.    By END USER

13.1.2.5.    By Country

13.1.2.5.1. Brazil

13.1.2.5.2. Argentina

13.1.2.5.3. Colombia

13.1.2.5.4. Rest of South America

14.  Competition Landscape

14.1.  Global Alectinib Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

14.2.  Global Alectinib Market Competition White Space Analysis, By Patient Type

14.3.  Global Alectinib Market Competition Heat Map Analysis, By Patient Type

14.4.  Global Alectinib Market Concentration & Company Market Shares (%) Analysis, 2022

15.  Company Profiles

15.1.                     Roche

15.1.1.   Company Overview & Key Stats

15.1.2.   Financial Performance & KPIs

15.1.3.   Product Portfolio

15.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

15.2.      Others

16.  Research Methodology

16.1.  External Transportations / Databases

16.2.  Internal Proprietary Database

16.3.  Primary Research

16.4.  Secondary Research

16.5.  Assumptions

16.6.  Limitations

16.7.  Report FAQs

17.  Research Findings & Conclusion

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.

Frequently Asked Questions

What is the market size of Alectinib Market in 2024?

Alectinib Market was valued at USD XX Million in 2024.

What is the growth rate for the Alectinib Market?

Alectinib Market size will increase at approximate CAGR of XX% during the forecasted period.

Which are the top companies operating within the market?

Major company operating within the Alectinib Market is Roche.

Which region dominates the Alectinib Market?

North America dominates the market with an active share of 49%.

CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $3750

Only Three Thousand Seven Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4750

Only Four Thousand Seven Hundred Fifty US dollar